Close

Recent Contrave Data is Positive for Orexigen's (OREX) Other Weight-Loss Candidate - Analyst

November 27, 2013 12:04 PM EST Send to a Friend
JPMorgan maintains an Overweight rating and $12 price target on Orexigen (Nasdaq: OREX) following the company's positive Contrave announcement earlier ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login